Growth factors

Worldwide Vascular Endothelial Growth Factor Inhibitor Industry to 2030 - Players Include Regeneron Pharmaceuticals, Astrazeneca & Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 6, 2021

Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

Key Points: 
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025.
  • The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

Retrieved on: 
Thursday, April 1, 2021

Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.

Key Points: 
  • Treatment or prevention of CIN with G-CSF has been the standard of care since Neupogen was approved in 1991.
  • There is a large unmet medical need and a growing market for CIN prevention and treatment in China as well.
  • According to IQVIA data, the G-CSF drug market (for CIN treatment) in China is growing at over 30% a year.
  • Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies.

HumanN Launches New SuperBeets® Memory & Focus Chews to Support Brain Health

Retrieved on: 
Thursday, March 25, 2021

SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.

Key Points: 
  • SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.
  • Blood flow to the brain, along with Brain-Derived Neurotrophic Factor (BDNF) - a key protein found in the brain - are important in promoting overall cognitive health.
  • SuperBeetsMemory & Focus features a highly pure form of Resveratrol produced through a unique fermentation process, along with a patented coffee fruit extract that have been clinically shown to help promote brain blood flow and support brain health, respectively.
  • Humann'sfull catalog of products, including the new SuperBeets Memory & Focus Chews is available online and on Amazon.

Global Chronic Kidney Disease Anemia Drug Forecast and Market Analysis 2021-2029: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Dominate the CKD Anemia Pipeline

Retrieved on: 
Monday, March 22, 2021

DUBLIN, March 22, 2021 /PRNewswire/ -- The "Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 22, 2021 /PRNewswire/ -- The "Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Furthermore, the China CKD anemia market is expected to experience the highest growth, increasing to $962M (14.6% of global market share) by 2029, at a CAGR of 9.9%.
  • The CKD anemia market is relatively well-established; many physicians believe that the existing therapies, namely ESAs, effectively control anemia for most patients.
  • Major drivers of growth in the CKD anemia market over the forecast period include: the launch and uptake of novel hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class across all markets covered in the report will drive the growth of the CKD anemia market.

Global $6.6 Billion Chronic Kidney Disease Anemia Drug Forecast and Market Analysis to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021

The "Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Kidney Disease Anemia - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to increase to $6.6B in 2029 at a Compound Annual Growth Rate (CAGR) of 3.4%.
  • Furthermore, the China CKD anemia market is expected to experience the highest growth, increasing to $962M (14.6% of global market share) by 2029, at a CAGR of 9.9%.
  • The CKD anemia market is relatively well-established; many physicians believe that the existing therapies, namely ESAs, effectively control anemia for most patients.

Global Recombinant Proteins Markets 2021-2026: Opportunities in the Rising Focus on Personalized Medicine & Protein Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 4, 2021

The global recombinant proteins market is projected to reach USD 1.7 billion by 2026 from USD 1 billion in 2021, at a CAGR of 9.8% during the forecast period.

Key Points: 
  • The global recombinant proteins market is projected to reach USD 1.7 billion by 2026 from USD 1 billion in 2021, at a CAGR of 9.8% during the forecast period.
  • Emerging markets in Asian countries and the rising focus on personalized medicine & protein therapeutics are other factors expected to offer strong growth opportunities for players in the recombinant proteins market.
  • In contrast, the declining cost of recombinant proteins may restrict market growth to a certain extent.
  • Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia-Pacific, and the Rest of the World.

Imvax abstracts accepted for presentation at AACR 2021 annual meeting

Retrieved on: 
Wednesday, March 3, 2021

"Our team is enthused by the continued momentum of this study and the impact IGV-001 might have on those fighting GBM."

Key Points: 
  • "Our team is enthused by the continued momentum of this study and the impact IGV-001 might have on those fighting GBM."
  • The investigational treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (insulin-like growth factor type 1 receptor).
  • Delivered through an implantable and removable biodiffusion chamber, antigenic products are released and initiate both an innate and adaptive immune response.
  • Imvax, Inc., headquartered in Philadelphia, PA, has an exclusive license agreement with Thomas Jefferson University granting it the right to develop and market this medical technology.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, February 12, 2021

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

China Recombinant Human Thrombopoietin Market Investigation Report 2021-2025

Retrieved on: 
Thursday, February 11, 2021

DUBLIN, Feb. 11, 2021 /PRNewswire/ -- The "Investigation Report on China's Recombinant Human Thrombopoietin Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 11, 2021 /PRNewswire/ -- The "Investigation Report on China's Recombinant Human Thrombopoietin Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • In 2005, Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. (trade name: TPIAO) was approved to be sold in China.
  • According to this market survey, the sales value of Recombinant Human Thrombopoietin kept rising after the drug was launched in China.
  • 2 Sales of Recombinant Human Thrombopoietin in China, 2015-2019
    2.3 Sales of Recombinant Human Thrombopoietin by Dosage Form in China, 2015-2019
    3 Analysis on Major Manufacturer of Recombinant Human Thrombopoietin in China, 2015-2019
    3.2 Shenyang Sunshine Pharmaceutical Co., Ltd.
    3.2.2 Sales of Recombinant Human Thrombopoietin by Shenyang Sunshine Pharmaceutical Co., Ltd. in China
    4 Prices of Recombinant Human Thrombopoietin in China, 2019-2020
    4.1 Shenyang Sunshine Pharmaceutical Co., Ltd. (TPIAO)
    5 Prospect of China's Recombinant Human Thrombopoietin Market, 2019-2023

Insights on the Erythropoietin (EPO) Global Market to 2030 - Identify Growth Segments for Investment

Retrieved on: 
Thursday, February 11, 2021

This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global erythropoietin (epo) market.
  • The global erythropoietin (EPO) market is expected to decline from $1.01 billion in 2019 to $0.95 billion in 2020 at a compound annual growth rate (CAGR) of -6.27%.
  • It compares the erythropoietin (epo) market with other segments of the erythropoietin (epo) market by size and growth, historic and forecast.
  • The erythropoietin (EPO) market consists of sales of erythropoietin drugs by entities (organizations, sole traders, and partnerships) that manufacture erythropoietin biosimilars.